A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
Latest Information Update: 29 Jan 2020
At a glance
- Drugs Raloxifene (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors Addpharma
- 29 Aug 2019 Status changed from recruiting to completed.
- 12 Dec 2018 New trial record